References of "Ansseau, Marc"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLa marche du sujet fibromyalgique et d’un sujet dépressif est-elle différenciable ? Exploration de deux affections « voisines » à partir d’un accéléromètre tri-axial.
Maquet, Didier ULg; Jaspar, J.; Lecart, Marie-Paule ULg et al

in Revue du Rhumatisme (2008), 75

Objectif : Analyser la marche de populations souffrant d’affections présentant certaines similitudes en termes de symptomatologie (fatigue, stress, anxiété, ralentissement psychomoteur, …) et pour ... [more ▼]

Objectif : Analyser la marche de populations souffrant d’affections présentant certaines similitudes en termes de symptomatologie (fatigue, stress, anxiété, ralentissement psychomoteur, …) et pour lesquelles le diagnostic différentiel apparaît parfois malaisé. Patients et méthodes : Cette étude inclut 32 sujets fibromyalgiques (46  10 ans), 20 sujets hospitalisés pour un état dépressif (49  14 ans) et 20 sujets volontaires contrôles (49  16 ans). L’analyse tri-dimensionnelle de la marche est réalisée à partir d'un système ambulatoire d'accélérométrie triaxial (Locometrix® Centaure Metrix, France) et d'une ligne de chronométrage. Le sujet marche à sa vitesse de confort, équipé de l'accéléromètre fixé à l'aide d'une ceinture élastique. L'épreuve, composée de 6 trajets rectilignes de 40 mètres, permet de suivre le profil des paramètres analysés tout au long de la distance totale parcourue (240 mètres). Les paramètres analysés sont : la vitesse de marche, la fréquence de pas, la longueur de pas, la symétrie et la régularité des pas, la puissance mécanique suivant les axes antéro-postérieur, crânio-caudal et médio-latéral, le coût énergétique. Résultats : La marche de la population fibromyalgique présente diverses altérations significatives non seulement en comparaison de la population contrôle mais aussi de la population dépressive. Nous observons chez le fibromyalgique une réduction significative (p < 0,05) de la vitesse de marche, de la longueur de pas, des activités suivant les axes antéro-postérieur et crânio-caudal. En outre, cette population présente une marche moins régulière (p < 0,05) alors que le coût énergétique de la marche est diminué (p < 0,05). Les paramètres de marche enregistrés au sein de la population dépressive apparaissent intermédiaires entre sujets contrôles et fibromyalgiques. Cependant, aucune modification significative ne s’observe entre populations contrôle et dépressive. Des travaux ultérieurs tenteront en outre de mettre en relation l’altération des paramètres de marche avec le degré d’anxiété et de dépression objectivé. Discussion : Bien que l’on évoque régulièrement un ralentissement fonctionnel chez les sujets souffrant de ces 2 affections « voisines », ce travail démontre que la marche d’un sujet dépressif et d’un sujet fibromyalgique semble différenciable. Ce dernier adopte une marche plus lente, moins régulière et visant à une « économie » d’énergie comme l’atteste le coût énergétique et les activités suivant les 3 axes. Conclusion : Cette épreuve pourrait constituer un outil original dans la caractérisation d’une population pathologique et le suivi longitudinal d’un patient. [less ▲]

Detailed reference viewed: 180 (31 ULg)
Full Text
Peer Reviewed
See detailUn cas de folie à trois.
hurlet, alice; parent, m; Lecoq, Arlette ULg et al

in Acta Psychiatrica Belgica (2008), 108

Detailed reference viewed: 117 (9 ULg)
Full Text
Peer Reviewed
See detailLes psychostimulants.
Pinto, Emmanuel ULg; Pitchot, William ULg; Ansseau, Marc ULg

in Revue Médicale de Liège (2008), 63

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailDopamine et dépression: le neurotransmetteur oublié.
Pitchot, William ULg; Scantamburlo, Gabrielle ULg; Ansseau, Marc ULg

in Revue Médicale de Liège (2008), 63

Detailed reference viewed: 51 (0 ULg)
Full Text
Peer Reviewed
See detailPeptides neurohypophysaires et dépression unipolaire: quel avenir?.
Scantamburlo, Gabrielle ULg; Pitchot, William ULg; Ansseau, Marc ULg et al

in Revue Médicale de Liège (2008), 63

Detailed reference viewed: 24 (2 ULg)
Full Text
Peer Reviewed
See detailNeurobiologie et pharmacothérapie du trouble obsessionnel-compulsif.
Ansseau, Marc ULg; Scantamburlo, Gabrielle ULg; Pinto, Emmanuel ULg et al

in Revue Médicale de Liège (2008), 63

Detailed reference viewed: 30 (1 ULg)
Full Text
Peer Reviewed
See detailL'augmentation des hospitalisations contraintes : un constat préoccupant.
Tortolani, Isabelle ULg; Gayetot, Delphine ULg; Duquesne, Patricia ULg et al

in Acta Psychiatrica Belgica (2008), 108

Detailed reference viewed: 139 (39 ULg)
Full Text
Peer Reviewed
See detailPlasma oxytocin levels and anxiety in patients with major depression
Scantamburlo, Gabrielle ULg; Hansenne, Michel ULg; Fuchs, Sonia et al

in Psychoneuroendocrinology (2007), 32(4), 407-410

Cerebrospinal fluid and plasmatic levels of oxytocin (OT) have been found to change in mood disorders. In post-mortem studies, the numbers of OT-expressing neurons in the paraventricular nucleus have been ... [more ▼]

Cerebrospinal fluid and plasmatic levels of oxytocin (OT) have been found to change in mood disorders. In post-mortem studies, the numbers of OT-expressing neurons in the paraventricular nucleus have been reported to be increased. Moreover, OT is considered as an endogenous antistress hormone. It has also revealed antidepressive effects. OT may contribute to the dysregulation of the HPA system in major depression. The aim of the study was to assess a possible relationship between anxiety and plasma oxytocin (OT) Levels in depressive patients. Severity of depression was estimated with the Hamilton Depression Rating Scale and anxiety by using the Spielberger State-Anxiety Inventory. Results showed a significant negative correlation between oxytocin and the scored symptoms depression (r = -0.58, p = 0.003) and anxiety (r = -0.61, p = 0.005). (C) 2007 Elsevier Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 182 (9 ULg)
Full Text
Peer Reviewed
See detailDepression and socio-econornic risk factors: 7-year longitudinal population study
Lorant, V.; Croux, C.; Weich, S. et al

in British Journal of Psychiatry (2007), 190

Background Low socio-economic status is associated with a higher prevalence of depression, but it is not yet known whether change in socio-economic status leads to a change in rates of depression. Aims To ... [more ▼]

Background Low socio-economic status is associated with a higher prevalence of depression, but it is not yet known whether change in socio-economic status leads to a change in rates of depression. Aims To assess whether longitudinal change in socio-economic factors affects change of depression level. Method In a prospective cohort study using the annual Belgian Household Panel Survey (1992-1999), depression was assessed using the Global Depression Scale. Socio-economic factors were assessed with regard to material standard of living, education, employment status and social relationships. Results A lowering in material standard of living between annual waves was associated with increases in depressive symptoms and caseness of major depression. Life circumstances also influenced depression. Ceasing to cohabit with a partner increased depressive symptoms and caseness, and improvement in circumstances reduced them; the negative effects were stronger than the positive ones. Conclusions The study showed a clear relationship between worsening socioeconomic circumstances and depression. [less ▲]

Detailed reference viewed: 42 (9 ULg)
Full Text
Peer Reviewed
See detail"Quand la dépression n'en finit pas... " Stratégies actuelles et perspectives thérapeutiques de la dépression résistante
Gayetot, Delphine ULg; Ansseau, Marc ULg; Triffaux, Jean-Marc ULg

in Revue Médicale de Liège (2007), 62(2), 103-11

All over the world, depression represents a major public health issue. According to WHO, it is the fifth disease in the world (in years of illness), the second for people aged 15 to 44 and by 2020, it ... [more ▼]

All over the world, depression represents a major public health issue. According to WHO, it is the fifth disease in the world (in years of illness), the second for people aged 15 to 44 and by 2020, it could become the second in the whole world population after cardiovascular diseases. Although increasingly safer and more efficient antidepressants are available, physicians are frequently confronted with the problem of resistant depression. Indeed, an estimated 30 to 45% of patients treated for major depressive disorder have either a partial response or no response at all to the antidepressive treatment. Residual symptoms are very common. Besides usual strategies such as lithium or thyroid hormones adding, some new approaches are now being used to improve the treatment of resistant depression. These are in particular pharmacological strategies such as switching or augmentation, psychotherapy and cerebral stimulation technology. This article reviews the latest clinical and therapeutic aspects of resistant depression. [less ▲]

Detailed reference viewed: 312 (7 ULg)
Full Text
Peer Reviewed
See detailPlasma oxytocin levels and anxiety in patients with major depression
Scantamburlo, Gabrielle ULg; Hansenne, Michel; Fuchs, Sonia et al

in Psychoneuroendocrinology (2007)

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailNeurophysins in mood disorders.
Scantamburlo, Gabrielle ULg; Ansseau, Marc ULg; Legros, Jean-Jacques ULg

in Neuropeptide Research Trends (2007)

Detailed reference viewed: 9 (0 ULg)
Full Text
See detailLes antidépresseurs.
Ansseau, Marc ULg; Pitchot, William ULg

in Guelfi, J. D.; Rouillon, F. (Eds.) Manuel de Psychiatrie (2007)

Detailed reference viewed: 20 (2 ULg)
Full Text
Peer Reviewed
See detailSyndrome de discontinuation associé aux antidépresseurs.
Pitchot, William ULg; Scantamburlo, Gabrielle ULg; Pinto, Emmanuel ULg et al

in Revue Médicale de Liège (2007), 62

Detailed reference viewed: 72 (7 ULg)
Full Text
Peer Reviewed
See detailNouveautés dans le traitement des troubles de l'humeur.
Pitchot, William ULg; Ansseau, Marc ULg

in Acta Psychiatrica Belgica (2007), 107

Detailed reference viewed: 40 (2 ULg)
Full Text
Peer Reviewed
See detailTherapeutic utilisations of vasopressin and oxytocin in mood disorders.
Scantamburlo, Gabrielle ULg; Pitchot, William ULg; Pinto, Emmanuel ULg et al

in Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (2007), 1

Detailed reference viewed: 72 (8 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Syndrome malin des neuroleptiques et paralysie generale
Foatelli, F. M.; gernay, p; Lievens, Isabelle ULg et al

in Revue Médicale de Liège (2006), 61(12), 807-11

Described in 1960 by Jean Delay in relation to the use of haloperidol, neuroleptic malignant syndrome remains relatively rare, and poorly known by the medical profession. The emergence of the atypical ... [more ▼]

Described in 1960 by Jean Delay in relation to the use of haloperidol, neuroleptic malignant syndrome remains relatively rare, and poorly known by the medical profession. The emergence of the atypical antipsychotic agents and preventive measures which have become general in recent years in hospital departments using dopamine receptor antagonists has not altered the prognosis, which remains potentially fatal in approximately a quarter of cases. This article proposes a descriptive summary of this syndrome in terms of clinical and biological diagnostics as well as of evolution, epidemiology, differential diagnosis and treatment. It describes the case of a patient affected by general paralysis having developed a neuroleptic malignant syndrome, thus the hypothesis what the neuroleptic malignant syndrome preferentially arises in subjects having underlying organic or metabolic problems and provides food for thought regarding the main medical and psychiatric overlaps, the use of dopaminergic agents and the behaviour to be adopted when dealing with a patient presenting with inaugural psychiatric symptomatology. [less ▲]

Detailed reference viewed: 58 (3 ULg)